|
Hello Immunization Partners,
Please share the following information with providers in your jurisdiction.
Emergency department visits associated with respiratory syncytial virus (RSV) among 0–1 year olds and hospitalizations due to RSV among 0–4 year olds are continuing to increase from week to week. RSV activity typically peaks between December and February (for more details on RSV trends, visit: Respiratory Disease Reports). Due to the ongoing increase in RSV incidence, the Michigan Department of Health and Human Services (MDHHS) Division of Immunization has extended the end of the season window for the administration of RSV monoclonal antibodies (mAb) nirsevimab (Beyfortus) or clesrovimab (Enflonsia) from March 31, 2026, to April 30, 2026, for infants and children.
The seasonal extension does not include the vaccination of pregnant women for RSV.
For those children who are 0-8 months of age and have not had an RSV mAb, providers should administer a dose through April 30, 2026. Although MCIR is currently forecasting for March 31, 2026, as the end of the season, providers should continue to vaccinate through April 30, 2026, while MCIR updates are being reviewed. Children born between May and September who are age eligible will be forecasted for the next RSV season (2026-2027) beginning October 1, 2026.
Guidelines remain the same for children, either nirsevmab (Beyfortus) or clesrovimab (Enflonsia) is recommended for infants less than 8 months of age born during or entering their first RSV season. There is no preferential recommendation for the use of either mAb.
Nirsevimab (Beyfortus) is the only mAb recommended for use in children 8 through 19 months who are at increased risk for severe RSV disease and entering their second RSV season.
For additional guidance, please use the following resources:
Nirsevimab-Guide-for-RSV.pdf
Clerovimab-Guide-for RSV.pdf
AAP-Immunization-Schedule.pdf
Timing of RSV Monoclonal Antibody Administration
Thank you for all you do,
MDHHS Immunization Outreach and Education Team
|
